Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

BACKGROUND: Programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hui, Geng, Ruixuan, Xu, Xiuxiu, Wang, Yingyi, Zhou, Jiaxin, Zhang, Shulan, Zhao, Lin, Guan, Mei, Bai, Chunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148956/
https://www.ncbi.nlm.nih.gov/pubmed/35651612
http://dx.doi.org/10.3389/fimmu.2022.893179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148956/
https://www.ncbi.nlm.nih.gov/pubmed/35651612
http://dx.doi.org/10.3389/fimmu.2022.893179

Ejemplares similares